Compare ProShares Ultra Semiconductors (USD) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Semiconductors vs GeneDx Holdings Corp — how do they compare? ProShares Ultra Semiconductors trades at $89.65, while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: ProShares Ultra Semiconductors is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| USD | WGS | |
|---|---|---|
Sector | Leveraged / Inverse | Technology |
52-Week High | $113.53 | $167.51 |
52-Week Low | $39.58 | $34.51 |
Market Cap | — | $1.80B |
Enterprise Value | — | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USD stock trades at $83.24, up 1.19% with a bearish technical signal from moving averages. The company shows limited financial data availability, with key valuation and profitability ratios not provided. Recent corporate actions include a future dividend announcement for June 2026. Technical indicators show neutral oscillators but bearish momentum signals with support at $82 and resistance at $86.
The outlook remains cautious due to bearish technical indicators and incomplete fundamental data. Investment opportunities depend on forthcoming financial disclosures, while risks include market volatility and the stock's current technical weakness. The neutral sentiment from oscillators suggests potential stabilization near current levels.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
